Saifullah
A 14-year-old boy from Pakistan with MRD-positive Pre-B ALL travelled to Beijing for CD19 CAR-T cell therapy after chemotherapy left residual disease behind.
Why the Family Contacted CancerFax
Facing rising MRD in a 14-year-old, Saifullah's family needed clear answers, not a list of hospitals. They had specific questions that were hard to resolve on their own from Pakistan, and they needed help separating credible options from noise.
Many hospitals mention CAR-T, but far fewer run established programmes for paediatric B-cell ALL with real case volume. Identifying them needed specialist knowledge.
CAR-T eligibility depends on the disease type, the CD19 marker, and the patient's overall condition. The family needed his reports reviewed against those criteria before travelling.
Documentation, medical translation, hospital communication, visas, and logistics for treatment in China were unfamiliar territory for the family.
"We were told the leukemia was still there and getting harder to treat. We did not know where to turn or whether CAR-T was even possible for our son. CancerFax helped us understand what was realistic and what to do next."β Saifullah's family
How CancerFax Helped
CancerFax worked as the family's navigator from the first message. The role was to organise the medical picture, identify an appropriate specialist centre, and remove the practical barriers to cross-border care, while leaving every clinical decision to the treating medical team.
Saifullah's bone marrow reports, flow cytometry, and MRD history were compiled into a structured case file so specialists could review the disease quickly and accurately.
CancerFax identified Lu Daopei Hospital in Beijing, a centre with deep experience in CAR-T cell therapy and bone marrow transplant for leukemia, as a suitable option for review.
Clinical documents were prepared and translated, and communication between the family and the hospital team was managed throughout the evaluation.
Visa documentation, accommodation guidance, and on-the-ground coordination were arranged for Saifullah and his accompanying family member.
Saifullah's Treatment Journey
Key steps from diagnosis to treatment and beyond.
Saifullah was diagnosed with Pre-B cell acute lymphoblastic leukemia and began treatment in Pakistan. Bone marrow studies and flow cytometric immunophenotyping were used to characterise the disease.
He received standard chemotherapy, with measurable residual disease tracked through follow-up bone marrow testing to check how completely the leukemia was being cleared.
MRD testing showed leukemic blasts persisting and rising from 0.16 percent to 0.35 percent of total cells. The cells were confirmed CD19-positive, marking them as a target for CD19-directed CAR-T therapy.
The family reached out to CancerFax. His reports were organised and reviewed against CAR-T eligibility considerations, and Lu Daopei Hospital in Beijing was identified as a centre with relevant experience.
With visa, translation, and logistics support arranged, Saifullah travelled to Lu Daopei Hospital, where the haematology team carried out its own evaluation of his case and confirmed the treatment plan.
Saifullah underwent CD19 CAR-T cell therapy at Lu Daopei Hospital under the care of its specialist team. He remains under post-treatment monitoring.
Every patient's treatment plan is individual. The pathway above describes this specific case β not a blueprint for others. Suitability for each treatment is determined by the treating clinical team based on each patient's individual clinical situation.
Where Saifullah Is Today
Saifullah completed CD19 CAR-T cell therapy at Lu Daopei Hospital and is under ongoing monitoring by the treating team. As with all CAR-T patients, careful follow-up, including repeat MRD assessment, is part of the standard course after treatment.
His family continues to stay in close contact with the hospital and with CancerFax for follow-up support.
β"Reaching the right hospital felt impossible from where we were. Having someone guide us step by step made all the difference for our son."ββ Saifullah's family
What Other Families Can Learn
Saifullah's journey offers practical takeaways for other families facing relapsed or MRD-positive childhood leukemia.
A low but rising residual disease level after chemotherapy is a signal to seek specialist review, not to wait. Acting while the child is strong keeps more options open.
CD19 CAR-T therapy only works against CD19-positive leukemia. Knowing the immunophenotype from flow cytometry tells you whether this path is even possible.
The opportunity to access advanced cellular therapy is best used while the patient is well enough to travel and undergo treatment safely.
Records, translation, hospital communication, and travel logistics can overwhelm a family. Specialist navigation removes those barriers so the focus stays on the child.
Related on CancerFax
Frequently Asked Questions
This patient story reflects an individual treatment journey. Outcomes vary from patient to patient. The information on this page should not be taken as medical advice or a guarantee of similar results. Treatment suitability depends on diagnosis, disease status, prior therapy, molecular findings, overall health, and specialist medical evaluation. Names and identifying details may be modified to protect patient privacy. All clinical decisions must be made in consultation with a qualified, licensed physician with access to the patient's complete medical information.
Need Help Understanding the Next Step?
If you or a loved one is facing a complex cancer diagnosis, relapse, or limited treatment options, CancerFax can help you organise the case, explore relevant hospitals and doctors, and understand whether advanced treatment or clinical trial pathways may be appropriate.
Β© CancerFax Β· Patient navigation and coordination platform. CancerFax is not a medical institution and does not provide medical treatment. All clinical care is provided by independent licensed physicians and hospitals. Patient names and identifying details are modified or anonymised where required to protect privacy. Story shared with documented family consent.